Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations
Latest Information Update: 30 Apr 2021
At a glance
- Drugs Anidulafungin (Primary) ; Fluconazole; Voriconazole
- Indications Candidaemia; Invasive candidiasis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 23 Apr 2021 Results Results of post hoc pooled analysis from NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; evaluating patient level efficacy and safety data of anidulafungin, published in the Clinical Drug Investigation
- 19 Mar 2020 Results (N=163) pharmacokinetic of Anidulafungin in pooled population analysis from 4 studies, published in the Clinical Pharmacology and Therapeutics
- 10 Jul 2019 New trial record